{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:05:36Z","timestamp":1761156336345},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.clinthera.2017.06.009","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T19:15:33Z","timestamp":1500318933000},"page":"1618-1627","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany"],"prefix":"10.1016","volume":"39","author":[{"given":"Nanxin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith A.","family":"Betts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Messali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha","family":"Skup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishvas","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.06.009_bib1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2017.06.009_bib2","first-page":"532","article-title":"Treatment of rheumatoid arthritis: a review of recommendations and emerging therapy","volume":"46","author":"Clements","year":"2011","journal-title":"Formulary J"},{"issue":"7 Suppl","key":"10.1016\/j.clinthera.2017.06.009_bib3","first-page":"S128","article-title":"Epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis: A Synopsis","volume":"20","author":"Gibofsky","year":"2014","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.clinthera.2017.06.009_bib4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2017.06.009_bib5","first-page":"123","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. Semin Arthritis","volume":"44","author":"Matcham","year":"2014","journal-title":"Rheumatism"},{"key":"10.1016\/j.clinthera.2017.06.009_bib6","first-page":"S43","article-title":"The consequences of rheumatoid arthritis: quality of life measures in the individual patient","volume":"23","author":"Pollard","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2017.06.009_bib7","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s10067-006-0240-3","article-title":"The burden of musculoskeletal disease--a global perspective","volume":"25","author":"Brooks","year":"2006","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.clinthera.2017.06.009_bib8","first-page":"401","article-title":"Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis","volume":"21","author":"Kim","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2017.06.009_bib9","doi-asserted-by":"crossref","first-page":"v48","DOI":"10.1093\/rheumatology\/kes122","article-title":"Developing an effective treatment algorithm for rheumatoid arthritis","volume":"51","author":"Keystone","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2017.06.009_bib10","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.06.009_bib11","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.06.009_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.06.009_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2017.06.009_bib14","first-page":"Cd007848","article-title":"Biologics for rheumatoid arthritis: an overview of Cochrane reviews","author":"Singh","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2017.06.009_bib15","doi-asserted-by":"crossref","DOI":"10.1186\/ar4428","article-title":"The ACR20 and defining a threshold for response in rheumatic diseases: too much of a good thing","volume":"16","author":"Felson","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2017.06.009_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrrheum.2010.45","article-title":"To switch or to change class-the biologic dilemma in rheumatoid arthritis","volume":"6","author":"Villeneuve","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.clinthera.2017.06.009_bib17","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1586\/erp.12.27","article-title":"When is switching warranted among biologic therapies in rheumatoid arthritis?","volume":"12","author":"Reynolds","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clinthera.2017.06.009_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3111\/13696998.2016.1142448","article-title":"Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system","volume":"19","author":"Rashid","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2017.06.009_bib19","unstructured":"Stetka BS, van Vollenhoven VF. New Rheumatoid Arthritis Management Guidelines: A Quick and Easy Guide. http:\/\/www.medscape.com\/viewarticle\/821404_10. Medscape Rheumatology, 2014."},{"issue":"5","key":"10.1016\/j.clinthera.2017.06.009_bib20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s12325-016-0318-5","article-title":"Economic burden of switching to a non-tumor necrosis factor inhibitor versus a tumor necrosis factor inhibitor biologic therapy among patients with rheumatoid arthritis","volume":"33","author":"Zhou","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2017.06.009_bib21","year":"2010","journal-title":"Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor"},{"key":"10.1016\/j.clinthera.2017.06.009_bib22","year":"2012","journal-title":"Transparency Committee Opinion - Mabthera"},{"key":"10.1016\/j.clinthera.2017.06.009_bib23","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.clinthera.2017.06.009_bib24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3111\/13696998.2014.893241","article-title":"Switching of biologic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis in a real world setting","volume":"17","author":"Meissner","year":"2014","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2017.06.009_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3111\/13696998.2015.1099538","article-title":"Real-world evaluation of TNF-inhibitor utilization in rheumatoid arthritis","volume":"19","author":"Harnett","year":"2016","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2017.06.009_bib26","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clinthera.2011.12.016","article-title":"Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study","volume":"34","author":"Bonafede","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.06.009_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-12-204","article-title":"Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study","volume":"12","author":"Ogale","year":"2011","journal-title":"BMC Musculoskel Disord"},{"key":"10.1016\/j.clinthera.2017.06.009_bib28","author":"Husni","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clinthera.2017.06.009_bib29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/ard.2005.039099","article-title":"Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study","volume":"65","author":"Nikas","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.06.009_bib30","article-title":"The, Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther","volume":"8","author":"Gomez-Reino","year":"2006"},{"key":"10.1016\/j.clinthera.2017.06.009_bib31","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2006.054742","article-title":"Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?","volume":"66","author":"Hjardem","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.06.009_bib32","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","article-title":"Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense","volume":"62","author":"van Vollenhoven","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.06.009_bib33","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/03009742.2012.729607","article-title":"Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort","volume":"42","author":"Chatzidionysiou","year":"2013","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.clinthera.2017.06.009_bib34","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.06.009_bib35","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/art.22520","article-title":"B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents","volume":"56","author":"Finckh","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2017.06.009_bib36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/annrheumdis-2013-203936","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor","volume":"74","author":"Harrold","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2017.06.009_bib37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/art.27227","volume":"62","author":"Hetland","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817307336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T15:05:26Z","timestamp":1575644726000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817307336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0149291817307336"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}